LLY

785.94

+1.92%↑

UNH

523.92

+1.97%↑

JNJ

142.08

-2.8%↓

ABBV

178.6

-0.56%↓

MRK

99.8

-1.22%↓

LLY

785.94

+1.92%↑

UNH

523.92

+1.97%↑

JNJ

142.08

-2.8%↓

ABBV

178.6

-0.56%↓

MRK

99.8

-1.22%↓

LLY

785.94

+1.92%↑

UNH

523.92

+1.97%↑

JNJ

142.08

-2.8%↓

ABBV

178.6

-0.56%↓

MRK

99.8

-1.22%↓

LLY

785.94

+1.92%↑

UNH

523.92

+1.97%↑

JNJ

142.08

-2.8%↓

ABBV

178.6

-0.56%↓

MRK

99.8

-1.22%↓

LLY

785.94

+1.92%↑

UNH

523.92

+1.97%↑

JNJ

142.08

-2.8%↓

ABBV

178.6

-0.56%↓

MRK

99.8

-1.22%↓

Search

Novo Nordisk A-S

Cerrado

Sector Salud

85.57 2.84

Resumen

Variación precio

24h

Actual

Mínimo

83.21

Máximo

85.77

Métricas clave

By Trading Economics

Ingresos

7.3B

27B

Ventas

3.3B

71B

P/B

Media del Sector

39.59

59.974

BPA

6.12

Rentabilidad por dividendo

1.258

Margen de beneficio

38.285

EBITDA

233M

36B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+34.69 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.26%

2.29%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

9.8B

298B

Apertura anterior

82.73

Cierre anterior

85.57

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

126 / 392 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Novo Nordisk A-S Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 dic 2024, 12:10 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Plunge After New Obesity Shot Falls Short of Expectations -- 2nd Update

20 dic 2024, 11:38 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Plunge After New Obesity Shot Falls Short of Expectations -- Update

8 ene 2025, 20:45 UTC

Principales Noticias

Donald Trump Wants Tariffs on Denmark Next. These Industries Would Be Hit Most. -- Barrons.com

8 ene 2025, 19:52 UTC

Principales Noticias

Donald Trump Wants Tariffs on Denmark Next. These Industries Would Be Hit Most. -- Barrons.com

8 ene 2025, 13:55 UTC

Charlas de Mercado

Novo Nordisk's CagriSema Selloff is Overdone, UBS Says -- Market Talk

7 ene 2025, 20:59 UTC

Principales Noticias

Trump's Danish Tariff Threat Means News Uncertainty for Ozempic Drugmaker Novo Nordisk -- Barrons.com

1 ene 2025, 08:30 UTC

Principales Noticias

Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com

30 dic 2024, 23:02 UTC

Adquisiciones, fusiones, absorciones

Novavax Completes Previously Announced $200M Sale of Czech Republic Manufacturing Site to Novo Nordisk

27 dic 2024, 07:00 UTC

Ganancias

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

26 dic 2024, 19:21 UTC

Principales Noticias

How to Prepare for a 'Lost Decade' in Stocks -- Barrons.com

25 dic 2024, 07:30 UTC

Principales Noticias

How to Prepare for a 'Lost Decade' in Stocks -- Barrons.com

23 dic 2024, 15:04 UTC

Principales Noticias

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

23 dic 2024, 09:22 UTC

Charlas de Mercado

Novo Nordisk Shares Should Recover Ground After Friday's Overreaction -- Market Talk

23 dic 2024, 08:59 UTC

Charlas de Mercado

Novo Nordisk Shares Rebound After Selloff -- Market Talk

23 dic 2024, 08:34 UTC

Charlas de Mercado

Novo Nordisk's Obesity Bubble Has Burst, Intron Health Says -- Market Talk

20 dic 2024, 21:32 UTC

Ganancias

These Stocks Moved the Most Today: FedEx, Novo Nordisk, Lilly, Tesla, DJT, Carnival, BlackBerry, U.S. Steel, Sirius XM, and More -- Barrons.com

20 dic 2024, 21:23 UTC

Ganancias
Acciones populares

Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla -- WSJ

20 dic 2024, 19:48 UTC

Principales Noticias

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints -- 2nd Update

20 dic 2024, 19:11 UTC

Ganancias

These Stocks Are Moving the Most Today: FedEx, Novo Nordisk, Lilly, Tesla, DJT, Carnival, BlackBerry, U.S. Steel, Sirius XM, and More -- Barrons.com

20 dic 2024, 18:07 UTC

Principales Noticias

There's a New Obesity King -- Heard on the Street -- WSJ

20 dic 2024, 16:57 UTC

Ganancias

These Stocks Are Moving the Most Today: FedEx, Novo Nordisk, Lilly, Tesla, DJT, Carnival, BlackBerry, U.S. Steel, Sirius XM, and More -- Barrons.com

20 dic 2024, 15:37 UTC

Charlas de Mercado

Novo Nordisk Trial Disappointment Puts Higher Onus on Next Studies -- Market Talk

20 dic 2024, 14:33 UTC

Charlas de Mercado

Novo Nordisk Setback Makes Market Think Eli Lilly Has Edge in Obesity Race -- Market Talk

20 dic 2024, 14:22 UTC

Principales Noticias

Novo Nordisk Moves to Boost Wegovy Supply in Bid to Ease Shortage -- Interview

20 dic 2024, 13:42 UTC

Ganancias

These Stocks Are Moving the Most Today: FedEx, Nike, Novo Nordisk, Lilly, Tesla, DJT, U.S. Steel, Occidental, and More -- Barrons.com

20 dic 2024, 12:07 UTC

Principales Noticias

Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. -- Barrons.com

20 dic 2024, 11:54 UTC

Charlas de Mercado

Novo Nordisk Shares Erase Year-to-Date Gains After Obesity Shot Disappoints -- Market Talk

20 dic 2024, 11:20 UTC

Principales Noticias

Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar. -- Barrons.com

19 dic 2024, 17:16 UTC

Principales Noticias

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dic 2024, 15:14 UTC

Principales Noticias

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S Esperado

Precio Objetivo

By TipRanks

34.69% repunte

Estimación a 12 meses

Media 112.25 USD  34.69%

Máximo 160 USD

Mínimo 81.5 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

4

Comprar

3

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 87.52Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

126 / 392 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.